

## Resolving Drug-Drug Interactions: A Guide for Community Pharmacies to Reduce Potential Hospitalizations

Wednesday, June 10, 2015

### Content Description:

This 2-hour workshop provides participants with a continuing professional development opportunity related to a particular set of evidence-based drug-drug interactions (DDIs) relevant in the care of older patients.

### Learning Objectives:

- To appreciate the significance of drug-drug interactions (DDIs) in the elderly population
- To understand current challenges in preventing DDIs
- To identify clinically significant DDIs involving commonly used antibiotics that are not consistently caught on clinical decision support systems (CDSS)
- To review alternative therapeutic options for empiric treatment of uncomplicated urinary tract infections (UTIs), group A streptococcal pharyngitis and community acquired pneumonia (CAP)
- To build confidence in mitigating DDIs with structured documentation forms to communicate drug therapy problems (DTPs) and patient-specific therapeutic recommendations to prescribers

### Program Abstract:

Drug-Drug Interactions (DDIs) represent a potential problem for patients that can lead to preventable adverse drug events, including unplanned hospital admission and serious patient harm, up to and including death. As the most accessible healthcare professional, community pharmacists are in a unique position to resolve potential DDIs by monitoring medication therapy and applying evidence-based pharmacotherapy knowledge. Older patients (i.e., age 65 and higher) are at increased risk of DDIs due to progression of chronic diseases, use of multiple medications, and physiological changes. Unfortunately, reliance on pre-programmed point of care clinical decision support systems limits the ability of pharmacists to become aware of recently published evidence-based DDIs. This workshop will provide participants with the tools to identify evidence-based DDIs found to increase the risk of hospitalizations, resolve specific evidence-based DDI pairs, and increase confidence in mitigating DDIs through structured communication with prescribers. A further gain through attendance at this workshop will be an improved awareness of professional cognitive services eligible for provincial reimbursement (e.g. Pharmaceutical Opinion Program in Ontario <http://www.health.gov.on.ca/en/pro/programs/drugs/pharmaopinion/>).

### Acknowledgement:

ISMP Canada would like to acknowledge support from the Canadian Foundation for Pharmacy's Innovation Fund Grant for the implementation of the "Safety Alerts as Drivers for Pharmaceutical Opinion Program" pilot research study (2012-2015).

### Audience:

Pharmacists, pharmacy interns, and students

**Workshop Level:** Intermediate (assumes prior knowledge and understanding of the fundamental concepts behind the different types and mechanisms of drug-drug interactions)

**Time:** Each workshop session is 2 hours in length; 3 timeslots are available:

- Session 1:** 8:30 a.m. – 10:30 a.m.
- Session 2:** 11:00 a.m. – 1:00 p.m.
- Session 3:** 2:00 p.m. – 4:00 p.m.

**Duration:** 2 hours

**Cost:** \$150 + HST per participant

**Speaker:** Atsushi Kawano, RPh, BSc, MSc, BScPhm

### Contact Us:

Telephone: 416-733-3131 Ext. 240  
Toll Free: 1-866-544-7672 Ext. 240  
E-mail: [education@ismp-canada.org](mailto:education@ismp-canada.org)  
Fax: 416-733-1146

### Location:

ISMP Canada  
Medication Safety Learning Centre  
4711 Yonge Street, Suite 501  
(Procter & Gamble building)  
Toronto, Ontario M2N 6K8

### CE Units:

The Canadian Council on Continuing Education in Pharmacy has accredited this program for 2 CEUs.  
(CCCEP File # 1260-2014-1242-L-P)





## Resolving Drug-Drug Interactions: A Guide for Community Pharmacies to Reduce Potential Hospitalizations

**Wednesday, June 10, 2015**

**Location:**

ISMP Canada  
Medication Safety Learning Centre  
4711 Yonge Street, Suite 501  
(Procter & Gamble building)  
Toronto, Ontario M2N 6K8

**How to Register:**

Fax: 416-733-1146, Attn: Registration

Mail: ISMP Canada, Attn: Registration  
4711 Yonge Street, Suite 501  
Toronto, Ontario M2N 6K8

Contact: Registration  
Phone: 416-733-3131 Ext. 240  
Toll Free: 1-866-544-7672 Ext. 240  
Email: registration@ismp-canada.org

### REGISTRATION INFORMATION (Please print clearly)

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_

Company Name: \_\_\_\_\_

Mailing Address: Business: \_\_\_\_\_

Home: \_\_\_\_\_

City: \_\_\_\_\_ Province: \_\_\_\_\_ Postal Code: \_\_\_\_\_

Telephone: \_\_\_\_\_ Fax: \_\_\_\_\_

Email (to be used for registration confirmation): \_\_\_\_\_

Dietary Restrictions: \_\_\_\_\_

#### Workshop Session

Select a timeslot:  8:30 a.m. – 10:30 a.m.  11:00 a.m. – 1:00 p.m.  2:00 p.m. – 4:00 p.m.

**Course Registration Fee** \$150 + HST per participant (Enrolment is limited to 8 attendees per session)\*

Total payable: \$ 169.50

\* ISMP Canada reserves the right to cancel or re-schedule the workshop if minimum enrolment is not reached

**Method of Payment** Cheques are payable to "ISMP Canada". Registration must be accompanied by payment.

Cheque  VISA®  Mastercard®

Name of Cardholder: \_\_\_\_\_

Credit Card #: \_\_\_\_\_ Expiry Date: \_\_\_\_\_

Signature: \_\_\_\_\_ GST Registration #898242219



**The Canadian Council on Continuing Education in Pharmacy has accredited this program for 2 CEUs.**  
(CCCEP File # 1260-2014-1242-L-P)

**Cancellation Policy:**

Requests for cancellations or refunds must be submitted in writing to ISMP Canada prior to Wednesday, June 3, 2015. A \$75.00 cancellation fee will apply. Cancellations will not be accepted after Wednesday, June 3, 2015.



# Resolving Drug-Drug Interactions: A Guide for Community Pharmacies to Reduce Potential Hospitalizations

**Wednesday, June 10, 2015**

**Location:** ISMP Canada,  
Medication Safety Learning Centre  
4711 Yonge Street, Suite 501,  
(Procter & Gamble building)  
Toronto, Ontario M2N 6K8

## AGENDA for ISMP Canada Workshop

### TIME:

Each workshop session is 2 hours in length; 3 timeslots are available:



**Session 1:**

8:30 a.m. – 10:30 a.m.



**Session 2:**

11:00 a.m. – 1:00 p.m.



**Session 3:**

2:00 p.m. – 4:00 p.m.

### PART 1:

Adverse Drug Reactions (ADRs) and Drug-Drug Interactions (DDIs) in the Elderly Population

### PART 2:

Evidence and Management of Clinically Relevant DDIs

### PART 3:

Tools to Communicate Drug Therapy Problems (DTPs) and Therapeutic Recommendations to Physicians

### PART 4:

Putting It All Together: A Case Example

### PART 5:

Testing Your Knowledge

### PART 6:

Conclusion